While the low number of events of cholangiocarcinoma in clinical trials precludes informative analyses [9,10,11,12,13,14], this safety signal is currently being monitored by the European Medicines Agency [15, 16]
We have convenient locations to serve you in Babylon NY, East Setauket NY, Forest Hills NY, Jericho NY, Lake Success NY, Melville NY, Mineola NY, Massapequa NY, New Hyde Park NY, and Riverhead NY
The cross-sectional design is a natural limitation making it impossible to determine causal relationships when evaluating the associations
SYMLIN administered subcutaneously immediately prior to a meal reduced plasma glucose concentrations following the meal when used with mealtime insulin (rapid-acting insulin analogs or regular human insulin) (Figure 2)
Patients concerned about regulatory compliance